PXS vs IMMX Comparison

Pyxis Tankers Inc is an international maritime transportation company focused on mid-sized eco-vessels for the product tanker and dry-bulk sectors. It owns a fleet that comprises double-hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Konkar Ormi, Pyxis Lamda, Konkar Venture, Pyxis Karteria, and others. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals. The company operates under two reportable segments, Tanker Vessels, which derive maximum revenue, and Dry-bulk Vessels.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.